Forskolin: Upcoming antiglaucoma molecule

Identification of a forskolin-like molecule in human renal cysts.

Renal cyst enlargement is increased by adenosine cAMP, which is produced within mural epithelial cells. In a search for modulators of cAMP synthesis cyst fluids from 18 patients with autosomal dominant or recessive polycystic kidney disease (PKD) were analyzed, and in 15 of them, a stable lipophilic molecule that increased cAMP levels, stimulated transepithelial chloride and fluid secretion, an...

Antiglaucoma pharmacotherapy

This review presents the pharmacotherapeutic approaches available in the treatment of glaucomatous optic neuropathy. Although its etiology is multi-factorial, currently, the main therapy is to decrease intraocular pressure. New therapies are being developed; the current trend is a retinal ganglion cell neuroprotection. Neuroprotection is achieved by combining antihypertensive agents with drugs ...

Pharmacokinetics of Antiglaucoma Medications

Pharmacokinetics may be simply defined as what the body does to the drug, as opposed to pharmacodynamics which may be defined as what the drug does to the body. This review is dedicated to the fate of antiglaucoma medications administerd externally. A special focus is made on the preservatives used in the antiglaucoma medications. Although from a pharmacokinetic point of view, these preservativ...

Cost Effectiveness of Antiglaucoma Medications

Glaucoma is the second-leading cause of acquired blindness, and the ques on of how to appropriately diagnose, treat, and manage the disease is of vital importance not only in maintaining pa ents' quality of life, but also in stemming the increasing burden on society imposed by the disease. With recent technological innova ons, increasing a en on has been focused on maintaining and increasing th...

Upcoming meetings